MARii and Sengenics ink MoU to develop ImmuSAFE™, a qualitative and quantitative COVID-19 test kit

The Malaysia Automotive, Robotics and IoT Institute (MARii) announced today that it has signed a Memorandum of Understanding with Sengenics Sdn Bhd that includes the development and commercialisation of products, services and technology related to health management systems, as well as high-throughput diagnostics for communicable diseases in industrial and commercial settings.

An important highlight of the MoU signing will be to support development of ImmuSAFETM, the world’s first ever qualitative and quantitative multi-epitope, multi-protein COVID-19 Antigen Test for detecting and quantifying whether an individual has protective levels of antibodies to SARS-CoV2.

The results generated on the ImmuSAFE test is fully quantitative, allowing for not just the measurement of absence or presence of antibodies; but also highly accurate determination of antibody levels. This is critical to ensure that the antibody levels present in an individual are protective following infection. This has wide ranging implications for industries and factories in terms of returning employees back to work.

“The COVID-19 situation has taught us that a mass outbreak not only halts our daily lives, but also the industries that are vital for the economy. In the age of digitalisation, it is important that digital technologies and the medical field begin cross-sectoral initiatives to protect the health and safety of all,” said Dato’ Madani Sahari, MARii CEO.

“The outcomes of this MoU will not only result in a significant breakthrough in our fight against COVID-19, but is an important milestone in the development of new medical products, services that are based on IoT-based technologies and accurate information derived from the unlimited possibilities in big data management”, he added.

Johan Hafiz bin Iskandar, Director of Sengenics, said, “We are excited to work with the MARii team in supporting their initiatives to reduce the economic impact of the COVID-19 pandemic on industry and look forward to integrating our diagnostics expertise with cutting-edge, real-time healthcare solutions at industry and factory level.”

Dato’ Madani also explained that Sengenics has already successfully produced functional recombinant antigens from SARS-CoV2 virus in its laboratories, making local COVID-19 vaccine development possible. A successful local vaccine development programme would place the country in a better position to combat the pandemic from within its own borders, otherwise fully depending on imported vaccines to cater to the millions of Malaysians that need them once a vaccine becomes available.

More information on the progress of the projects above will be released by MARii in the near future.

Address: Block 2280, Jalan Usahawan 2, Cyber 6, 63000, Cyberjaya, Selangor.


Tel: (+60) 03-8318 7742

Fax: (+60) 03-8318 7743

  • Instagram
  • Facebook Social Icon
  • LinkedIn Social Icon

Follow Us On Our Social Media

Contact Us